MEDIA

Press Releases

Select Year

FDA Accepts Revance Resubmission for Frown Line Therapy

Will A Biotech Rival Finally Shake Up Abbvie’s $2B Botox Cosmetic Franchise? Revance Will Find Out Soon

Revance Set For September FDA Decision on Botox Rival

FDA Accepts Revance Resubmission for Frown Line Treatment

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines

FDA Accepts BLA Resubmission for DAXI Injections